nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—ABCC1—Mitoxantrone—lymphatic system cancer	0.294	0.475	CbGbCtD
Zoledronate—ABCC1—Vincristine—lymphatic system cancer	0.202	0.327	CbGbCtD
Zoledronate—ABCC1—Methotrexate—lymphatic system cancer	0.122	0.198	CbGbCtD
Zoledronate—Angiopathy—Vincristine—lymphatic system cancer	0.000585	0.00153	CcSEcCtD
Zoledronate—Diarrhoea—Teniposide—lymphatic system cancer	0.000584	0.00153	CcSEcCtD
Zoledronate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000581	0.00152	CcSEcCtD
Zoledronate—Chest pain—Bleomycin—lymphatic system cancer	0.000574	0.0015	CcSEcCtD
Zoledronate—Myalgia—Bleomycin—lymphatic system cancer	0.000574	0.0015	CcSEcCtD
Zoledronate—Alopecia—Vincristine—lymphatic system cancer	0.00057	0.00149	CcSEcCtD
Zoledronate—Back pain—Carmustine—lymphatic system cancer	0.000569	0.00149	CcSEcCtD
Zoledronate—Discomfort—Bleomycin—lymphatic system cancer	0.000567	0.00148	CcSEcCtD
Zoledronate—Mental disorder—Vincristine—lymphatic system cancer	0.000565	0.00148	CcSEcCtD
Zoledronate—Chills—Mitoxantrone—lymphatic system cancer	0.000564	0.00148	CcSEcCtD
Zoledronate—Neoplasm—Methotrexate—lymphatic system cancer	0.000563	0.00148	CcSEcCtD
Zoledronate—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000561	0.00147	CcSEcCtD
Zoledronate—Alopecia—Mitoxantrone—lymphatic system cancer	0.000555	0.00145	CcSEcCtD
Zoledronate—Confusional state—Bleomycin—lymphatic system cancer	0.000554	0.00145	CcSEcCtD
Zoledronate—Vision blurred—Carmustine—lymphatic system cancer	0.000554	0.00145	CcSEcCtD
Zoledronate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000553	0.00145	CcSEcCtD
Zoledronate—Tremor—Carmustine—lymphatic system cancer	0.000551	0.00144	CcSEcCtD
Zoledronate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00055	0.00144	CcSEcCtD
Zoledronate—Oedema—Bleomycin—lymphatic system cancer	0.00055	0.00144	CcSEcCtD
Zoledronate—Erythema—Mitoxantrone—lymphatic system cancer	0.000547	0.00143	CcSEcCtD
Zoledronate—Infection—Bleomycin—lymphatic system cancer	0.000546	0.00143	CcSEcCtD
Zoledronate—Anaemia—Carmustine—lymphatic system cancer	0.000544	0.00142	CcSEcCtD
Zoledronate—Back pain—Vincristine—lymphatic system cancer	0.000543	0.00142	CcSEcCtD
Zoledronate—Vomiting—Teniposide—lymphatic system cancer	0.000543	0.00142	CcSEcCtD
Zoledronate—Agitation—Carmustine—lymphatic system cancer	0.00054	0.00142	CcSEcCtD
Zoledronate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000538	0.00141	CcSEcCtD
Zoledronate—Asthenia—Fludarabine—lymphatic system cancer	0.000538	0.00141	CcSEcCtD
Zoledronate—Rash—Teniposide—lymphatic system cancer	0.000538	0.00141	CcSEcCtD
Zoledronate—Dermatitis—Teniposide—lymphatic system cancer	0.000538	0.00141	CcSEcCtD
Zoledronate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000535	0.0014	CcSEcCtD
Zoledronate—Headache—Teniposide—lymphatic system cancer	0.000535	0.0014	CcSEcCtD
Zoledronate—Pruritus—Fludarabine—lymphatic system cancer	0.000531	0.00139	CcSEcCtD
Zoledronate—Back pain—Mitoxantrone—lymphatic system cancer	0.000529	0.00139	CcSEcCtD
Zoledronate—Leukopenia—Carmustine—lymphatic system cancer	0.000526	0.00138	CcSEcCtD
Zoledronate—Anorexia—Bleomycin—lymphatic system cancer	0.000524	0.00137	CcSEcCtD
Zoledronate—Anaemia—Vincristine—lymphatic system cancer	0.000519	0.00136	CcSEcCtD
Zoledronate—Agitation—Vincristine—lymphatic system cancer	0.000516	0.00135	CcSEcCtD
Zoledronate—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000515	0.00135	CcSEcCtD
Zoledronate—Hypotension—Bleomycin—lymphatic system cancer	0.000514	0.00135	CcSEcCtD
Zoledronate—Diarrhoea—Fludarabine—lymphatic system cancer	0.000513	0.00134	CcSEcCtD
Zoledronate—Convulsion—Carmustine—lymphatic system cancer	0.00051	0.00133	CcSEcCtD
Zoledronate—Hypertension—Carmustine—lymphatic system cancer	0.000508	0.00133	CcSEcCtD
Zoledronate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000507	0.00133	CcSEcCtD
Zoledronate—Nausea—Teniposide—lymphatic system cancer	0.000507	0.00133	CcSEcCtD
Zoledronate—Anaemia—Mitoxantrone—lymphatic system cancer	0.000505	0.00132	CcSEcCtD
Zoledronate—Vertigo—Vincristine—lymphatic system cancer	0.000504	0.00132	CcSEcCtD
Zoledronate—Leukopenia—Vincristine—lymphatic system cancer	0.000503	0.00132	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000501	0.00131	CcSEcCtD
Zoledronate—Chest pain—Carmustine—lymphatic system cancer	0.000501	0.00131	CcSEcCtD
Zoledronate—Myalgia—Carmustine—lymphatic system cancer	0.000501	0.00131	CcSEcCtD
Zoledronate—Anxiety—Carmustine—lymphatic system cancer	0.000499	0.00131	CcSEcCtD
Zoledronate—Paraesthesia—Bleomycin—lymphatic system cancer	0.000494	0.00129	CcSEcCtD
Zoledronate—Malaise—Mitoxantrone—lymphatic system cancer	0.000493	0.00129	CcSEcCtD
Zoledronate—Dyspnoea—Bleomycin—lymphatic system cancer	0.00049	0.00128	CcSEcCtD
Zoledronate—Renal failure acute—Methotrexate—lymphatic system cancer	0.00049	0.00128	CcSEcCtD
Zoledronate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000489	0.00128	CcSEcCtD
Zoledronate—Convulsion—Vincristine—lymphatic system cancer	0.000486	0.00127	CcSEcCtD
Zoledronate—Hypertension—Vincristine—lymphatic system cancer	0.000485	0.00127	CcSEcCtD
Zoledronate—Confusional state—Carmustine—lymphatic system cancer	0.000484	0.00127	CcSEcCtD
Zoledronate—Oedema—Carmustine—lymphatic system cancer	0.00048	0.00126	CcSEcCtD
Zoledronate—Decreased appetite—Bleomycin—lymphatic system cancer	0.000478	0.00125	CcSEcCtD
Zoledronate—Myalgia—Vincristine—lymphatic system cancer	0.000478	0.00125	CcSEcCtD
Zoledronate—Cough—Mitoxantrone—lymphatic system cancer	0.000477	0.00125	CcSEcCtD
Zoledronate—Infection—Carmustine—lymphatic system cancer	0.000477	0.00125	CcSEcCtD
Zoledronate—Vomiting—Fludarabine—lymphatic system cancer	0.000477	0.00125	CcSEcCtD
Zoledronate—Convulsion—Mitoxantrone—lymphatic system cancer	0.000474	0.00124	CcSEcCtD
Zoledronate—Rash—Fludarabine—lymphatic system cancer	0.000473	0.00124	CcSEcCtD
Zoledronate—Dermatitis—Fludarabine—lymphatic system cancer	0.000472	0.00124	CcSEcCtD
Zoledronate—Hypertension—Mitoxantrone—lymphatic system cancer	0.000472	0.00124	CcSEcCtD
Zoledronate—Pain—Bleomycin—lymphatic system cancer	0.00047	0.00123	CcSEcCtD
Zoledronate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00047	0.00123	CcSEcCtD
Zoledronate—Headache—Fludarabine—lymphatic system cancer	0.00047	0.00123	CcSEcCtD
Zoledronate—Tachycardia—Carmustine—lymphatic system cancer	0.000468	0.00123	CcSEcCtD
Zoledronate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000466	0.00122	CcSEcCtD
Zoledronate—Myalgia—Mitoxantrone—lymphatic system cancer	0.000466	0.00122	CcSEcCtD
Zoledronate—Chest pain—Mitoxantrone—lymphatic system cancer	0.000466	0.00122	CcSEcCtD
Zoledronate—Anxiety—Mitoxantrone—lymphatic system cancer	0.000464	0.00122	CcSEcCtD
Zoledronate—Lethargy—Methotrexate—lymphatic system cancer	0.000462	0.00121	CcSEcCtD
Zoledronate—Discomfort—Mitoxantrone—lymphatic system cancer	0.00046	0.0012	CcSEcCtD
Zoledronate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000458	0.0012	CcSEcCtD
Zoledronate—Oedema—Vincristine—lymphatic system cancer	0.000458	0.0012	CcSEcCtD
Zoledronate—Anorexia—Carmustine—lymphatic system cancer	0.000458	0.0012	CcSEcCtD
Zoledronate—Infection—Vincristine—lymphatic system cancer	0.000455	0.00119	CcSEcCtD
Zoledronate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000453	0.00119	CcSEcCtD
Zoledronate—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000452	0.00119	CcSEcCtD
Zoledronate—Confusional state—Mitoxantrone—lymphatic system cancer	0.00045	0.00118	CcSEcCtD
Zoledronate—Nervous system disorder—Vincristine—lymphatic system cancer	0.000449	0.00118	CcSEcCtD
Zoledronate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000449	0.00118	CcSEcCtD
Zoledronate—Hypotension—Carmustine—lymphatic system cancer	0.000449	0.00118	CcSEcCtD
Zoledronate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000446	0.00117	CcSEcCtD
Zoledronate—Oedema—Mitoxantrone—lymphatic system cancer	0.000446	0.00117	CcSEcCtD
Zoledronate—Nausea—Fludarabine—lymphatic system cancer	0.000446	0.00117	CcSEcCtD
Zoledronate—Infection—Mitoxantrone—lymphatic system cancer	0.000443	0.00116	CcSEcCtD
Zoledronate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000443	0.00116	CcSEcCtD
Zoledronate—Shock—Mitoxantrone—lymphatic system cancer	0.000439	0.00115	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000437	0.00115	CcSEcCtD
Zoledronate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000437	0.00114	CcSEcCtD
Zoledronate—Urticaria—Bleomycin—lymphatic system cancer	0.000437	0.00114	CcSEcCtD
Zoledronate—Anorexia—Vincristine—lymphatic system cancer	0.000437	0.00114	CcSEcCtD
Zoledronate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000436	0.00114	CcSEcCtD
Zoledronate—Body temperature increased—Bleomycin—lymphatic system cancer	0.000435	0.00114	CcSEcCtD
Zoledronate—Insomnia—Carmustine—lymphatic system cancer	0.000434	0.00114	CcSEcCtD
Zoledronate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000433	0.00114	CcSEcCtD
Zoledronate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000431	0.00113	CcSEcCtD
Zoledronate—Paraesthesia—Carmustine—lymphatic system cancer	0.000431	0.00113	CcSEcCtD
Zoledronate—Hypotension—Vincristine—lymphatic system cancer	0.000428	0.00112	CcSEcCtD
Zoledronate—Dyspnoea—Carmustine—lymphatic system cancer	0.000428	0.00112	CcSEcCtD
Zoledronate—Somnolence—Carmustine—lymphatic system cancer	0.000427	0.00112	CcSEcCtD
Zoledronate—Anorexia—Mitoxantrone—lymphatic system cancer	0.000425	0.00111	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000417	0.00109	CcSEcCtD
Zoledronate—Decreased appetite—Carmustine—lymphatic system cancer	0.000417	0.00109	CcSEcCtD
Zoledronate—Hypotension—Mitoxantrone—lymphatic system cancer	0.000417	0.00109	CcSEcCtD
Zoledronate—Insomnia—Vincristine—lymphatic system cancer	0.000414	0.00109	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000414	0.00109	CcSEcCtD
Zoledronate—Paraesthesia—Vincristine—lymphatic system cancer	0.000411	0.00108	CcSEcCtD
Zoledronate—Pain—Carmustine—lymphatic system cancer	0.00041	0.00108	CcSEcCtD
Zoledronate—Constipation—Carmustine—lymphatic system cancer	0.00041	0.00108	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000407	0.00107	CcSEcCtD
Zoledronate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000405	0.00106	CcSEcCtD
Zoledronate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000401	0.00105	CcSEcCtD
Zoledronate—Decreased appetite—Vincristine—lymphatic system cancer	0.000398	0.00104	CcSEcCtD
Zoledronate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000398	0.00104	CcSEcCtD
Zoledronate—Somnolence—Mitoxantrone—lymphatic system cancer	0.000397	0.00104	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000396	0.00104	CcSEcCtD
Zoledronate—Feeling abnormal—Carmustine—lymphatic system cancer	0.000396	0.00104	CcSEcCtD
Zoledronate—Fatigue—Vincristine—lymphatic system cancer	0.000395	0.00103	CcSEcCtD
Zoledronate—Asthenia—Bleomycin—lymphatic system cancer	0.000395	0.00103	CcSEcCtD
Zoledronate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000393	0.00103	CcSEcCtD
Zoledronate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000393	0.00103	CcSEcCtD
Zoledronate—Pain—Vincristine—lymphatic system cancer	0.000392	0.00103	CcSEcCtD
Zoledronate—Constipation—Vincristine—lymphatic system cancer	0.000392	0.00103	CcSEcCtD
Zoledronate—Asthma—Methotrexate—lymphatic system cancer	0.000391	0.00102	CcSEcCtD
Zoledronate—Pruritus—Bleomycin—lymphatic system cancer	0.000389	0.00102	CcSEcCtD
Zoledronate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000388	0.00102	CcSEcCtD
Zoledronate—Fatigue—Mitoxantrone—lymphatic system cancer	0.000385	0.00101	CcSEcCtD
Zoledronate—Constipation—Mitoxantrone—lymphatic system cancer	0.000382	0.001	CcSEcCtD
Zoledronate—Pain—Mitoxantrone—lymphatic system cancer	0.000382	0.001	CcSEcCtD
Zoledronate—Body temperature increased—Carmustine—lymphatic system cancer	0.000379	0.000994	CcSEcCtD
Zoledronate—Abdominal pain—Carmustine—lymphatic system cancer	0.000379	0.000994	CcSEcCtD
Zoledronate—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000375	0.000982	CcSEcCtD
Zoledronate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000375	0.000982	CcSEcCtD
Zoledronate—Pancytopenia—Methotrexate—lymphatic system cancer	0.000371	0.000973	CcSEcCtD
Zoledronate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000368	0.000963	CcSEcCtD
Zoledronate—Neutropenia—Methotrexate—lymphatic system cancer	0.000366	0.000958	CcSEcCtD
Zoledronate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000365	0.000956	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000363	0.000952	CcSEcCtD
Zoledronate—Body temperature increased—Vincristine—lymphatic system cancer	0.000362	0.000949	CcSEcCtD
Zoledronate—Abdominal pain—Vincristine—lymphatic system cancer	0.000362	0.000949	CcSEcCtD
Zoledronate—Urticaria—Mitoxantrone—lymphatic system cancer	0.000355	0.000929	CcSEcCtD
Zoledronate—Hypersensitivity—Carmustine—lymphatic system cancer	0.000354	0.000926	CcSEcCtD
Zoledronate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000353	0.000924	CcSEcCtD
Zoledronate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000353	0.000924	CcSEcCtD
Zoledronate—Vomiting—Bleomycin—lymphatic system cancer	0.00035	0.000916	CcSEcCtD
Zoledronate—Infestation—Methotrexate—lymphatic system cancer	0.000349	0.000913	CcSEcCtD
Zoledronate—Infestation NOS—Methotrexate—lymphatic system cancer	0.000349	0.000913	CcSEcCtD
Zoledronate—Depression—Methotrexate—lymphatic system cancer	0.000348	0.000911	CcSEcCtD
Zoledronate—Rash—Bleomycin—lymphatic system cancer	0.000347	0.000908	CcSEcCtD
Zoledronate—Dermatitis—Bleomycin—lymphatic system cancer	0.000346	0.000907	CcSEcCtD
Zoledronate—Asthenia—Carmustine—lymphatic system cancer	0.000344	0.000902	CcSEcCtD
Zoledronate—Renal failure—Methotrexate—lymphatic system cancer	0.000343	0.000898	CcSEcCtD
Zoledronate—Stomatitis—Methotrexate—lymphatic system cancer	0.00034	0.00089	CcSEcCtD
Zoledronate—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000339	0.000888	CcSEcCtD
Zoledronate—Hypersensitivity—Vincristine—lymphatic system cancer	0.000338	0.000884	CcSEcCtD
Zoledronate—Haematuria—Methotrexate—lymphatic system cancer	0.000332	0.000871	CcSEcCtD
Zoledronate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000329	0.000861	CcSEcCtD
Zoledronate—Asthenia—Vincristine—lymphatic system cancer	0.000329	0.000861	CcSEcCtD
Zoledronate—Diarrhoea—Carmustine—lymphatic system cancer	0.000328	0.00086	CcSEcCtD
Zoledronate—Nausea—Bleomycin—lymphatic system cancer	0.000327	0.000856	CcSEcCtD
Zoledronate—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000325	0.000852	CcSEcCtD
Zoledronate—Asthenia—Mitoxantrone—lymphatic system cancer	0.00032	0.000839	CcSEcCtD
Zoledronate—Dizziness—Carmustine—lymphatic system cancer	0.000317	0.000832	CcSEcCtD
Zoledronate—Diarrhoea—Vincristine—lymphatic system cancer	0.000314	0.000821	CcSEcCtD
Zoledronate—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000309	0.00081	CcSEcCtD
Zoledronate—Urethral disorder—Methotrexate—lymphatic system cancer	0.000307	0.000804	CcSEcCtD
Zoledronate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000305	0.0008	CcSEcCtD
Zoledronate—Vomiting—Carmustine—lymphatic system cancer	0.000305	0.0008	CcSEcCtD
Zoledronate—Dizziness—Vincristine—lymphatic system cancer	0.000303	0.000794	CcSEcCtD
Zoledronate—Rash—Carmustine—lymphatic system cancer	0.000303	0.000793	CcSEcCtD
Zoledronate—Dermatitis—Carmustine—lymphatic system cancer	0.000302	0.000792	CcSEcCtD
Zoledronate—Headache—Carmustine—lymphatic system cancer	0.000301	0.000788	CcSEcCtD
Zoledronate—Eye disorder—Methotrexate—lymphatic system cancer	0.000292	0.000766	CcSEcCtD
Zoledronate—Vomiting—Vincristine—lymphatic system cancer	0.000291	0.000763	CcSEcCtD
Zoledronate—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00029	0.000761	CcSEcCtD
Zoledronate—Rash—Vincristine—lymphatic system cancer	0.000289	0.000757	CcSEcCtD
Zoledronate—Dermatitis—Vincristine—lymphatic system cancer	0.000289	0.000756	CcSEcCtD
Zoledronate—Headache—Vincristine—lymphatic system cancer	0.000287	0.000752	CcSEcCtD
Zoledronate—Nausea—Carmustine—lymphatic system cancer	0.000285	0.000747	CcSEcCtD
Zoledronate—Angiopathy—Methotrexate—lymphatic system cancer	0.000284	0.000744	CcSEcCtD
Zoledronate—Vomiting—Mitoxantrone—lymphatic system cancer	0.000284	0.000743	CcSEcCtD
Zoledronate—Immune system disorder—Methotrexate—lymphatic system cancer	0.000283	0.00074	CcSEcCtD
Zoledronate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000282	0.000739	CcSEcCtD
Zoledronate—Rash—Mitoxantrone—lymphatic system cancer	0.000281	0.000737	CcSEcCtD
Zoledronate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000281	0.000736	CcSEcCtD
Zoledronate—Chills—Methotrexate—lymphatic system cancer	0.000281	0.000736	CcSEcCtD
Zoledronate—Headache—Mitoxantrone—lymphatic system cancer	0.00028	0.000732	CcSEcCtD
Zoledronate—Alopecia—Methotrexate—lymphatic system cancer	0.000277	0.000724	CcSEcCtD
Zoledronate—Mental disorder—Methotrexate—lymphatic system cancer	0.000274	0.000718	CcSEcCtD
Zoledronate—Erythema—Methotrexate—lymphatic system cancer	0.000272	0.000714	CcSEcCtD
Zoledronate—Malnutrition—Methotrexate—lymphatic system cancer	0.000272	0.000714	CcSEcCtD
Zoledronate—Nausea—Vincristine—lymphatic system cancer	0.000272	0.000713	CcSEcCtD
Zoledronate—Dysgeusia—Methotrexate—lymphatic system cancer	0.000267	0.000699	CcSEcCtD
Zoledronate—Nausea—Mitoxantrone—lymphatic system cancer	0.000265	0.000694	CcSEcCtD
Zoledronate—Back pain—Methotrexate—lymphatic system cancer	0.000264	0.00069	CcSEcCtD
Zoledronate—Vision blurred—Methotrexate—lymphatic system cancer	0.000257	0.000673	CcSEcCtD
Zoledronate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000253	0.000662	CcSEcCtD
Zoledronate—Anaemia—Methotrexate—lymphatic system cancer	0.000252	0.00066	CcSEcCtD
Zoledronate—Malaise—Methotrexate—lymphatic system cancer	0.000246	0.000644	CcSEcCtD
Zoledronate—Vertigo—Methotrexate—lymphatic system cancer	0.000245	0.000641	CcSEcCtD
Zoledronate—Leukopenia—Methotrexate—lymphatic system cancer	0.000244	0.000639	CcSEcCtD
Zoledronate—Cough—Methotrexate—lymphatic system cancer	0.000238	0.000623	CcSEcCtD
Zoledronate—Convulsion—Methotrexate—lymphatic system cancer	0.000236	0.000618	CcSEcCtD
Zoledronate—Arthralgia—Methotrexate—lymphatic system cancer	0.000232	0.000608	CcSEcCtD
Zoledronate—Myalgia—Methotrexate—lymphatic system cancer	0.000232	0.000608	CcSEcCtD
Zoledronate—Chest pain—Methotrexate—lymphatic system cancer	0.000232	0.000608	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00023	0.000603	CcSEcCtD
Zoledronate—Discomfort—Methotrexate—lymphatic system cancer	0.000229	0.0006	CcSEcCtD
Zoledronate—Confusional state—Methotrexate—lymphatic system cancer	0.000224	0.000587	CcSEcCtD
Zoledronate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000222	0.000582	CcSEcCtD
Zoledronate—Infection—Methotrexate—lymphatic system cancer	0.000221	0.000579	CcSEcCtD
Zoledronate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000218	0.000571	CcSEcCtD
Zoledronate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000218	0.00057	CcSEcCtD
Zoledronate—Skin disorder—Methotrexate—lymphatic system cancer	0.000216	0.000566	CcSEcCtD
Zoledronate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000215	0.000563	CcSEcCtD
Zoledronate—Anorexia—Methotrexate—lymphatic system cancer	0.000212	0.000555	CcSEcCtD
Zoledronate—Hypotension—Methotrexate—lymphatic system cancer	0.000208	0.000544	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000203	0.000531	CcSEcCtD
Zoledronate—Insomnia—Methotrexate—lymphatic system cancer	0.000201	0.000527	CcSEcCtD
Zoledronate—Paraesthesia—Methotrexate—lymphatic system cancer	0.0002	0.000523	CcSEcCtD
Zoledronate—Dyspnoea—Methotrexate—lymphatic system cancer	0.000198	0.000519	CcSEcCtD
Zoledronate—Somnolence—Methotrexate—lymphatic system cancer	0.000198	0.000518	CcSEcCtD
Zoledronate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000196	0.000513	CcSEcCtD
Zoledronate—Decreased appetite—Methotrexate—lymphatic system cancer	0.000193	0.000506	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000192	0.000503	CcSEcCtD
Zoledronate—Fatigue—Methotrexate—lymphatic system cancer	0.000192	0.000502	CcSEcCtD
Zoledronate—Pain—Methotrexate—lymphatic system cancer	0.00019	0.000498	CcSEcCtD
Zoledronate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000183	0.00048	CcSEcCtD
Zoledronate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000182	0.000476	CcSEcCtD
Zoledronate—Urticaria—Methotrexate—lymphatic system cancer	0.000177	0.000463	CcSEcCtD
Zoledronate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000176	0.00046	CcSEcCtD
Zoledronate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000176	0.00046	CcSEcCtD
Zoledronate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000164	0.000429	CcSEcCtD
Zoledronate—Asthenia—Methotrexate—lymphatic system cancer	0.00016	0.000418	CcSEcCtD
Zoledronate—Pruritus—Methotrexate—lymphatic system cancer	0.000157	0.000412	CcSEcCtD
Zoledronate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000152	0.000399	CcSEcCtD
Zoledronate—Dizziness—Methotrexate—lymphatic system cancer	0.000147	0.000385	CcSEcCtD
Zoledronate—Vomiting—Methotrexate—lymphatic system cancer	0.000141	0.00037	CcSEcCtD
Zoledronate—Rash—Methotrexate—lymphatic system cancer	0.00014	0.000367	CcSEcCtD
Zoledronate—Dermatitis—Methotrexate—lymphatic system cancer	0.00014	0.000367	CcSEcCtD
Zoledronate—Headache—Methotrexate—lymphatic system cancer	0.000139	0.000365	CcSEcCtD
Zoledronate—Nausea—Methotrexate—lymphatic system cancer	0.000132	0.000346	CcSEcCtD
